enzalutamide in the non-metastatic setting for crpc
Published 5 years ago • 89 plays • Length 0:42Download video MP4
Download video MP3
Similar videos
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
1:19
nonmetastatic crpc: meeting an unmet need
-
10:26
expert comment: antiandrogens in nonmetastatic crpc | tomasz beer
-
4:47
treatment challenges in nonmetastatic crpc
-
0:57
dr. dorff on choosing between therapies in nonmetastatic crpc
-
6:50
ep. 6: identifying nonmetastatic crpc
-
5:20
apalutamide in treating nonmetastatic crpc
-
2:34
asco: bone effects fuel optimism for prostate ca drug
-
21:25
an update on the prosper trial: focusing on nonmetastatic crpc
-
1:45
dr. choudhury on antiandrogen treatment selection in nonmetastatic crpc
-
5:52
clinical trials in non-metastatic crpc
-
22:16
understanding non metastatic castration resistant prostate cancer with dr. hamilton
-
5:55
the future of treatment for nonmetastatic crpc
-
6:51
understanding nonmetastatic crpc: an overview
-
3:06
enzalutamide in the context of nonmetastatic crpc
-
2:24
delaying disease progression in early, non-metastatic crpc treatment
-
5:05
castrate resistant, non-metastatic prostate cancer (m0 state) | prostate cancer staging guide
-
5:01
fda d.i.s.c.o.: a new drug approval for non-metastatic castration-resistant prostate cancer
-
1:48
dr. bradley on impact of spartan and prosper in nonmetastatic crpc